Preparation and Evaluation of Nanoliposomal Formulation of Glatiramer Acetate for Treatment of Multiple Sclerosis

سال انتشار: 1398
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 484

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

NIMED03_181

تاریخ نمایه سازی: 7 آبان 1398

چکیده مقاله:

Multiple sclerosis (MS) is an autoimmune disease of the CNS in which cellular immunity and inflammatory cytokines lead to loss ofmyelin. Glatiramer acetate is a random copolymer of 4 amino acids, approved for treatment of MS. Due to site and glomerular elimination of glatiramer acetate after subcutaneous injection, we determined to design its liposomal form in which some properties of drug suchas size are modulated to prevent its hydrolysis and also leading to stimulation of humoral immunity. Materials and Methods: The liposomes were produced through film method with various percentage of different phopholipids. Then size, zeta potential, percentage ofencapsulation were evaluated. Cellular cytotoxicity will measured by MTT assay. The liposomal formulation of Glatiramer Acetate will be injected subcutaneously to C57BL/6 mice to evaluate immunological response and titration of cytokines. The effectiveness of this newformulation then will be compared to the conventional form of drug by inducing experimental autoimmune encephalomyelitis (EAE) in the aforementioned mice. Results: Three best formulation of liposomal Glatiramer Acetate (Dipalmitoylphosphatidylcholine D i p a l m i t o y l p h o s p h a t i d y l g l y c e r o l e , D i st e a r o y l p h o s p h a t i d y l c h o l i n e , Distearoylphosphatidylglycerol, Dimyristoyl phosphatidylcholine, Dimyristoylphosphatidylglycerol and Cholestrole) had the Z Average of about 300nm, PDI of about 0.1 and zeta potential of about 25. These three formulations reduced the proliferation in macrophage and fibroblast cells (J774 and NIH) in a concentration- dependent manner. Conclusion: It seems that liposomal form of glatiramer acetate has the potential to use as novel form of drug for treatment of MS with more efficacy and more duration of action than the conventional form of Glatiramer Acetate that will enhance compliance of patients.

نویسندگان

Niloufar Rahiman

Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Mahmoud Reza Jafari

Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran